[The ophthalmic zona-ipsilateral cerebral ischemia syndrome].

P. Bec,F. Camuzet,P. Maillard,A. Mathis,J. Arné

1986-10-01

Abstract:

What problem does this paper attempt to address?

[Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease].

Fang Ning You,Liang Luo,Xiang Jun Liu,Xue Wu Zhang,Chun Li

2023-01-01

Abstract:OBJECTIVE:To investigate the fetal and maternal outcomes, risk factors of disease progression and adverse pregnancy outcomes (APOs) in patients with undifferentiated connective tissue disease (UCTD). METHODS:This retrospective study described the outcomes of 106 pregnancies in patients with UCTD. The patients were divided into APOs group (n=53) and non-APOs group (n=53). The APOs were defined as miscarriage, premature birth, pre-eclampsia, premature rupture of membranes (PROM), intrauterine growth restriction (IUGR), postpartum hemorrhage (PPH), and stillbirth, small for gestational age infant (SGA), low birth weight infant (LBW) and birth defects. The differences in clinical manifestations, laboratory data and pregnancy outcomes between the two groups were compared. Logistic regression analysis was performed to analyze the risk factors for APOs and the progression of UCTD to definitive CTD. RESULTS:There were 99 (93.39%) live births, 4 (3.77%) stillbirths and 3 (2.83%) miscarriage, 20 (18.86%) preterm delivery, 6 (5.66%) SGA, 17 (16.03%) LBW, 11 (10.37%) pre-eclampsia, 7 (6.60%) cases IUGR, 19 (17.92%) cases PROM, 10 (9.43%) cases PPH. Compared with the patients without APOs, the patients with APOs had a higher positive rate of anti-SSA antibodies (73.58% vs. 54.71%, P=0.036), higher rate of leukopenia (15.09% vs. 3.77%, P=0.046), lower haemoglobin level [109.00 (99.50, 118.00) g/L vs. 124.00 (111.50, 132.00) g/L, P < 0.001].Multivariate Logistic regression analysis showed that leucopenia (OR=0.82, 95%CI: 0.688-0.994) was an independent risk factors for APOs in UCTD (P=0.042). Within a mean follow-up time of 5.00 (3.00, 7.00) years, the rate of disease progression to a definite CTD was 14.15%, including 8 (7.54%) Sjögren's syndrome, 4 (3.77%) systemic lupus erythematosus (SLE), 4 (3.77%) rheumatoid arthritis and 1 (0.94%) mixed connective tissue disease. Multivariate Cox proportional risk regression analysis showed that Raynaud phenomenon (HR=40.157, 95%CI: 3.172-508.326) was an independent risk factor for progression to SLE. CONCLUSION:Leukopenia is an independent risk factor for the development of APOs in patients with UCTD. Raynaud's phenmon is a risk factor for the progression of SLE. Tight disease monitoring and regular follow-up are the key measures to prevent adverse pregnancy outcomes and predict disease progression in UCTD patients with pregnancy.
Research Progress on the Relationship between Anticardiolipin Antibodies and Adverse Pregnancy Outcomes

Qi WU,Dan-qing CHEN

DOI: https://doi.org/10.3969/j.issn.1674-1870.2017.06.004

2017-01-01

Abstract:Antiphospholipid antibodies are a group of antibodies with specificity for binding to negatively charged phospholipids on the cell surface, including anticardiolipin antibodies, lupus coagulation inhibitor and anti-beta 2-glycoprotein I antibodies. They can cause a series of characteristic clinical symptoms, which are referred to as antiphospholipid syndrome. There is an international consensus on the classification criteria for definite antiphospholipid syndrome. Numerous studies have shown that anticardiolipin antibodies are associated with several adverse pregnancy outcomes, such as infertility, abortion, stillbirth, preeclampsia, placental insufficiency and so on. But its pathogenic mechanism is not yet clear. However, some investigators believe that anticardiolipin antibodies are not the main cause of adverse pregnancy outcomes. This paper focuses on the association between anticardiolipin antibodies and adverse pregnancy outcomes. And it also suggests investigators to optimize the experimental design and diagnostic criteria for classification, hopes to obtain more authoritative results using to guide clinical practice.
Discharge pattern of tonically activated motor units during unloading.

L. Gerilovsky,A. Struppler,F. Velho,O. Niehage

1990-12-01

Abstract:In order to analyse the EMG pattern during unloading of brachial biceps muscle, the interference EMG and single motor unit activity were investigated. The measurements were done on seven healthy subjects with two types of unloading techniques: a) active unloading, when the subjects resisted against an external load (10, 20, 30 and 40 N) which is suddenly released, and b) passive unloading, performed by low inertia torque motors with independently adjustable background extension and suddenly applied flexion torques. Following active unloading the silent period duration, the amplitude of the rebound and its segmentation into consecutive bursts is changing with initial load, whereas the silent period latency remains constant. Following passive unloading the acceleration influences predominantly the amplitude of the rebound, without changing its latency and silent period duration. The initial voluntary activity influences both silent period duration and rebound parameters (latency, amplitude and duration).
Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies

Wendy Marder,Jason S Knight,Mariana J Kaplan,Emily C Somers,Xu Zhang,Alexander A O'Dell,Vasantha Padmanabhan,Richard W Lieberman

DOI: https://doi.org/10.1136/lupus-2015-000134

2016-04-27

Abstract:Objective: Systemic lupus erythematosus (SLE) is associated with increased risk of adverse pregnancy outcomes, including pre-eclampsia, particularly in association with antiphospholipid antibody syndrome (APS). While significant placental abnormalities are expected in pre-eclampsia, less is known about how lupus activity and APS in pregnancy affect the placenta. We describe placental pathology from a population of lupus pregnancies, several of which were complicated by APS-related thromboses, in which pre-eclampsia and other complications developed. We performed standard histopathological placental review and quantified neutrophils and neutrophil extracellular traps (NETs) in the intervillous space, given the recognised association of NETs with lupus, APS and pre-eclampsia. Methods: Pre-eclampsia, SLE and control placentas were scored for histological features, and neutrophils were quantified on H&E and immunohistochemical staining for the granular protein myeloperoxidase. NETs were identified by extracellular myeloperoxidase staining in the setting of decondensed nuclei. Non-parametric analysis was used to evaluate differences in netting and intact neutrophils between groups, with Kruskal-Wallis testing for associations between histological findings and neutrophils. Results: Placentas were evaluated from 35 pregnancies: 10 controls, 11 pre-eclampsia, 4 SLE+pre-eclampsia and 10 SLE, including one complicated by catastrophic APS and one complicated by hepatic and splenic vein thromboses during pregnancy. Intrauterine growth restriction and oligohydramnios were observed in lupus cases but not controls. Significantly more NETs were found infiltrating placental intervillous spaces in pre-eclampsia, SLE+pre-eclampsia and all 10 SLE non-pre-eclampsia cases. The ratio of NETs to total neutrophils was significantly increased in all case groups compared with controls. When present, NETs were associated with maternal vasculitis, laminar decidual necrosis, maternal-fetal interface haemorrhage and non-occlusive fetal thrombotic vasculopathy. Conclusions: In this pilot study of placental tissue from lupus pregnancies, outcomes were more complicated, particularly if associated with APS. Placental tissue revealed marked inflammatory and vascular changes that were essentially indistinguishable from placental tissue of pre-eclampsia pregnancies.
OA22 Pregnancy in connective tissue diseases: a 30 year follow-up study of 465 pregnancies from a Spanish monocentric registry

Cristiana Sieiro Santos,Paula Pérez García,Jose Ordas Martínez,Carolina Álvarez Castro,Elvira Díez Álvarez

DOI: https://doi.org/10.1093/rheumatology/keae163.022

2024-04-01

Rheumatology

Abstract:Abstract Background/Aims Pregnancy in patients with connective tissue diseases (CTDs) are known to be at high risk for the occurrence of adverse pregnancy outcomes. We aimed to evaluate pregnancy outcomes in patients with systemic lupus erythematosus (SLE), systemic sclerosis (SSc), primary Sjögren’s syndrome (pSS) and undifferentiated connective tissue disease (UCTD). Methods A retrospective and descriptive study was conducted from 1990 to 2020. All data were collected from the medical records of women of childbearing age with SLE, SSc, SS and UTCD enrolled in our clinic at the time of their pregnancy and childbirth. The obstetric, maternal and fetal outcomes were collected and compared regarding diagnosis and adverse outcomes. Results The study group included 295 patients: 125 patients (42%) with SLE; 50 patients (17%) with SSc; 80 patients (27%) with pSS; 40 patients (14%) with UCTD. A total of 465 pregnancies were registered. The mean age at delivery was 31.5±8.5 years and the mean duration of disease was 7.2±5.6 years. Pregnancy loss occurred in 21% of patients, live births in 66% of pregnancies, preterm delivery in 8%, postpartum haemorrhage in 6%, preeclampsia in 5%, placental abnormalities in 4%, ectopic pregnancy in 3%, and premature rupture of membranes in 2%. Treatment with hydroxychloroquine (HCQ) was received in 115 pregnancies in SLE (59%), 21 pregnancies in SSc (24%) 62 pregnancies in pSS (52%) and 32 pregnancies in UCTD (49%). Exposure to corticosteroids and biologics during pregnancy was 23 (18.4%), 6 (12%), 15 (19%) and 3 (7.5%), respectively. Patients with SLE had a higher risk of fetal morbidity, including abortion (p = 0.03), mean abortion rate (p = 0.03), preeclampsia (p = 0.04), ectopic pregnancy (p = 0.03), preterm delivery (p = 0.02) and postpartum haemorrhage (p = 0.01) than patients without SLE. The multivariate model found an association between unfavourable pregnancy outcomes and disease activity (OR 2.4; 95% CI 1.3-7.2; p 0.003), whilst HCQ during pregnancy (OR 0.23; 95% CI 0.03-0.82) had a protective effect. Conclusion 66% of pregnancies in patients with autoimmune diseases resulted in live births. Patients with SLE had higher rates of fetal and maternal morbidity than SSc, pSS and UCTD. Disease activity was associated with unfavourable pregnancy outcomes. Exposure to HCQ had a protective effect during pregnancy. Disclosure C. Sieiro Santos: None. P. Pérez García: None. J. Ordas Martínez: None. C. Álvarez Castro: None. E. Díez Álvarez: None.

rheumatology
Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?

Arsenio Spinillo,Fausta Beneventi,Roberto Caporali,Veronique Ramoni,Carlomaurizio Montecucco

DOI: https://doi.org/10.1111/aji.12762

2017-09-16

American Journal of Reproductive Immunology

Abstract:Undifferentiated connective tissue diseases (UCTDs) are a heterogeneous group of disorders characterized by symptoms and signs suggestive of systemic autoimmune rheumatic disease (ARD), but which do not fulfill all the established criteria for definite diagnosis of a condition. Although a third of UCTDs can progress to a definite ARD within months or years, most UCTDs can remain stable for years with minimal disease activity. The annual incidence of UCTD in the general population ranges from 14 to 140 per 100 000 people. UCTDs are associated with the persistence of several circulating autoantibodies including antinuclear, antiphospholipid or antithyroid antibodies. Immunological evaluation of subjects with UCTDs suggests a proinflammatory state and dysregulation of the Th1/Th2 balance. Autoantibodies have well-known deleterious effects on placentation and have been associated with an increased risk of prematurity, fetal growth restriction (FGR), preeclampsia, and congenital atrioventricular heart block. Although epidemiological and biological data suggest a potential negative impact on reproductive outcomes, the relationship between UCTD and pregnancy outcomes has not been adequately studied. While awaiting definitive data from large studies, obstetricians should be aware that rheumatic disorders in their early, incomplete, or undifferentiated phases can adversely affect pregnancy outcomes, increasing the likelihood of pregnancy loss, FGR, preeclampsia, and prematurity.

immunology,reproductive biology
Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Xiaodong Li,Abdullah Shopit,Jingmin Wang

DOI: https://doi.org/10.1007/s00404-021-06178-5

Abstract:Background: Autoimmune diseases as antiphospholipid syndrome (APS) and systemic lupus erythematosus (SLE) could cause many maternal complications. The most common maternal complications of autoimmune diseases are lupus flare, hypertension, nephritis, preeclampsia (PE), eclampsia, and poor pregnancy outcomes which including preterm delivery and pregnancy loss. Only the lupus anticoagulant in the greatest prospective multicenter study has been associated with adverse pregnancy outcomes of the APS. Purpose: This review aims to provide a comprehensive update for predictors in pregnant women with APS/SLE. Methods: These data have been collected from clinical and pathological studies, systematic reviews, and meta-analysis. Results: In recent years the SLE and APS demonstrated to have different and valuable clinical and biomarker predictors for the pregnancy outcome. Treatment of pregnant women with APS is low molecular weight heparin (LMWH) and aspirin; however, around 75% of this management is considered successful. Conclusion: This review summarizes recent research that focuses on biochemical and clinical predictors of adverse pregnancy outcomes (APOs) of pregnant women with SLE and APS. Furthermore, we have collected more evidence that confirms the safety and efficacy of hydroxychloroquine (HCQ) preventing APOs.
Related Factors of Fetal Loss in Chinese Women with Systemic Lupus Erythematosus: Data from Chinese SLE Treatment and Research Group Registry IV

Xinping Tian,Mengtao Li,Zhizhong Ye,Xiao Zhang,Shengyun Liu,Lijun Wu,Li Ma,Liqi Bi,Xiaoxia Zuo,Lingyun Sun,Cibo Huang,Jiuliang Zhao,Fengchun Zhang,Yan Zhao,Xiaofeng Zeng

DOI: https://doi.org/10.1111/1756-185x.12542

2014-01-01

International Journal of Rheumatic Diseases

Abstract:ObjectiveTo study the factors associated with fetal loss in Chinese women with systemic lupus erythematosus (SLE) in a large cohort of SLE patients in the CSTAR (Chinese SLE Treatment and Research Group) registry.MethodsWe compared the clinical characteristics and auto-antibody profiles between SLE patients with fetal loss and SLE patients with normal pregnancies. The relationship between selected variables and fetal loss was examined by univariate analysis and binary logistic regression analysis.ResultsA total of 992 patients with 2026 pregnancies were recruited. Fifty women experienced fetal loss, including 49 spontaneous abortion, eight stillbirths and three neonatal deaths. The overall fetal loss rate was 3.0% (60/2026). Arthritis and serositis were observed significantly more frequently (P<0.05) in normal pregnancy women. The rate of thrombocytopenia was significantly increased in patients with fetal loss (30.0% vs. 16.1%, P=0.010), while there was no statistically significant difference in the frequency of nephropathy, central nervous system involvement between the normal pregnancy group and fetal loss group. Factors that associated with fetal loss included anti-phospholipid antibodies (aPL) (OR 2.299; 95% CI 1.058-4.993; P=0.035) and anti-Sjogren syndrome antigen A (SSA) antibody (OR 2.283; 95% CI 1.275-4.088; P=0.005), and thrombocytopenia (OR 2.241; 95% CI 1.192-4.213; P=0.012). However, arthritis (OR 0.544, 95% CI 0.307-0.965, P=0.037) was associated with favorable fetal outcome.ConclusionsBoth univariate analysis and binary logistic regression analysis suggest that thrombocytopenia, aPL antibodies and anti-SSA antibody are associated with fetal loss in Chinese SLE women, while arthritis may be a possible factor related to favorable pregnancy outcome.
Placental damage in pregnancies with systemic lupus erythematosus: A narrative review

Aleida Susana Castellanos Gutierrez,Francesc Figueras,Diana M Morales-Prieto,Ekkehard Schleußner,Gerard Espinosa,Núria Baños

DOI: https://doi.org/10.3389/fimmu.2022.941586

2022-08-17

Abstract:Systemic lupus erythematosus (SLE) is a chronic inflammatory autoimmune disease of unknown cause, which mainly affects women of childbearing age, especially between 15 and 55 years of age. During pregnancy, SLE is associated with a high risk of perinatal morbidity and mortality. Among the most frequent complications are spontaneous abortion, fetal death, prematurity, intrauterine Fetal growth restriction (FGR), and preeclampsia (PE). The pathophysiology underlying obstetric mortality and morbidity in SLE is still under investigation, but several studies in recent years have suggested that placental dysfunction may play a crucial role. Understanding this association will contribute to developing therapeutic options and improving patient management thus reducing the occurrence of adverse pregnancy outcomes in this group of women. In this review, we will focus on the relationship between SLE and placental insufficiency leading to adverse pregnancy outcomes.
Pregnancy outcomes and risk factors analysis in patients with systemic lupus erythematous

Jing Lu,Dan Xu,Qianqian Wan,Huijun Chen

DOI: https://doi.org/10.1186/s12884-024-06701-x

2024-07-22

Abstract:Background: The management of systemic lupus erythematosus (SLE) during pregnancy remains a challenge currently. Identifying early predictors of adverse pregnancy outcomes in SLE patients can help to develop treatment plan and improve prognosis. The aim of this study is to explore the clinical and laboratory variables in the early pregnancy that can predict adverse neonatal and maternal outcomes, thereby facilitating the grading management of SLE. Methods: A retrospective analysis was conducted on 126 pregnant women with SLE who were admitted to Zhongnan Hospital of Wuhan University between January 2017 and December 2022. All enrolled patients were diagnosed (including newly diagnosed and previously diagnosed) during first trimester of pregnancy and their clinical records, laboratory results and pregnancy outcomes were reviewed. The association between the clinical and laboratory characteristics of patients at 12 gestational age and the adverse neonatal (ANOs) as well as maternal outcomes (AMOs) were analyzed. Results: A total of 117 live births (92.8%) were recorded in the study. ANOs occurred in 59 (46.8%) cases, including fetal loss in 9 cases (7.1%), preterm birth in 40 cases (31.7%), small for gestational (SGA) in 15 cases (11.9%), and complete heart block in 2 cases (1.5%). Univariate analysis showed that disease activity index (P < 0.0001), lupus nephritis (P = 0.0195), anti-SSB positivity (P = 0.0074) and hypocomplementemia (P = 0.0466) were related to ANOs. However, multivariate analysis showed that only disease activity during early pregnancy was an independent predictor for ANOs (OR = 7.053, 95% CI: 1.882 to 26.291, P = 0.004). In addition, 48 patients experienced AMOs during subsequent trimester, including 24 (19.0%) patients with disease flare and 23 (18.3%) patients with pre-eclampsia. Unplanned pregnancy (P = 0.010), active disease (P = 0.0004), new onset SLE (P = 0.0044) and lupus nephritis (P = 0.0009) were associated with AMOs in univariate analysis, while disease activity was identified as an independent risk factor for AMOs (OR = 2.553, 95% CI: 1.012-6.440, P = 0.047). Conclusion: Active disease in early pregnancy is associated with adverse pregnancy outcomes. For patients with high risk factor for ANOs and AMOs, more intensive treatment and follow-up should be a wise measure. Especially for those who suffer from active disease, they should be fully informed and given the option to terminate or continue their pregnancy.
Effects of Perinatal Disease Activity on Offspring's Growth in Patients with Systemic Lupus Erythematosus

Yu Wei,Yun Zhu,Jia Tang,Jie Li,Zhiqun Wang,Ziyi Jin,Jun Liang,Bingzhu Hua,Cheng Zhao,Hong Wang,Xuebing Feng

DOI: https://doi.org/10.5114/aoms/154929

2022-01-01

Abstract:IntroductionTo systematically analyze the associations of perinatal disease activity with adverse outcomes of Chinese patients with systemic lupus erythematosus (SLE) and their offspring.Material and methodsData of prenatal SLE patients and healthy pregnant woman admitted to our hospital during October 2001 to January 2018 were retrospectively collected, and the status of SLE offspring was followed-up in March 2020. Disease activity was evaluated by SLE disease activity index 2000 (SLEDAI-2k), and those with scores > 6 were defined as having active disease.ResultsTotally 198 deliveries of 194 SLE patients and 199 deliveries of healthy women were documented. Maternal and fetal adverse outcomes occurred in 74 (37.4%) and 90 (45.5%) deliveries of SLE patients respectively, which was significantly higher than those of healthy subjects. Among SLE patients, the active group had higher rates of gestational hypertension (p<0.001), preeclampsia/eclampsia (p<0.001), low birth weight (p<0.001), premature birth (p<0.001) and fetal growth restriction (FGR) (p<0.01) than inactive group. Multivariate logistic analysis revealed that perinatal renal activity was associated with gestational hypertension (OR 4.43, p<0.001), preeclampsia/ eclampsia (OR 9.14, p<0.001), low birth weight (OR 2.24, p<0.05) and premature birth (OR 4.20, p<0.001). Compared with the general population, SLE offspring had relatively high rates of eczema (50/142 35.2%) and congenital heart disease (6/142 4.2%), which were irrelevant to perinatal disease activity, but related to specific antibodies.ConclusionsFor perinatal SLE women, renal activity is associated with a variety of adverse pregnancy outcomes. However, maternal perinatal disease activity does not seem to affect the growth of their offspring.
A Comparison of Obstetric Outcomes in Antiphospholipid Syndrome Among Pregnant Women With Systemic Lupus Erythematosus

Dur E Shahwar,Duriya Rehmani,Amir Raza

DOI: https://doi.org/10.7759/cureus.62126

2024-06-11

Cureus

Abstract:Objective The aim of this study was to evaluate the maternal and perinatal outcomes in systemic lupus erythematosus (SLE) women with antiphospholipid syndrome (APS). Methods This retrospective case-control study was conducted among pregnant women with SLE with and without APS. Group A included SLE patients with APS, whereas group B included pregnant SLE women without APS. Data were expressed as mean ± standard deviation (SD). Frequency and percentage were computed for categorical data. The chi-square test was used to analyze the difference between categorical data. Results Out of 125 cases of SLE, APS was found in 72 (57.6%) women. Almost 95.8% of patients were on treatment (aspirin and enoxaparin) in group A. Preterm delivery (31.89±7.36 versus 34.46±4.97; p=0.021) and termination of pregnancy (18.1% [13/72] versus 5.7% [3/53]; p=0.04) were statistically significant in group A. Among these terminations, second-trimester intrauterine death is found to be more in group A (SLE with APS) (16.7% [12/72]) as compared to group B (SLE without APS) (5.7% [3/53]) with a p-value of 0.05. Perinatal outcomes including NICU admissions (39% [23/59] versus 24% [12/50]; p=0.071) and neonatal death (12.3% [7/57]; p=0.015) were also found to be statistically significant between the two groups. Conclusion APS with SLE is associated with adverse pregnancy outcomes such as preterm birth, termination of pregnancy due to second-trimester fetal loss, more NICU admission, and neonatal deaths when compared to the control group. Hence, pregnancies with APS with SLE require vigilant monitoring and frequent follow-ups to ensure a positive pregnancy outcome.
High-risk factors for adverse pregnancy outcomes in systemic lupus erythaematosus: a retrospective study of a Chinese population

Meng Jiang,Yanling Chang,You Wang,Qiong Fu,Sihan Lin,Jiayue Wu,Wen Di

DOI: https://doi.org/10.1136/bmjopen-2021-049807

IF: 3.006

2021-11-01

BMJ Open

Abstract:Objective To clarify high-risk factors for adverse pregnancy outcomes (APOs) in systemic lupus erythaematosus (SLE). Design A retrospective chart review study. Setting Data were collected in a tertiary medical centre, Shanghai, China, from November 2010 to December 2018. Participants A total of 513 pregnancies with SLE were retrospectively analysed. Twenty-seven patients who underwent artificial abortions due to personal reasons were excluded. Primary outcome measures APOs were primary outcomes, including foetal loss, premature birth, small for gestational age (SGA), asphyxia neonatorum, composite foetal APOs and hypertensive disorders of pregnancy (HDP). Multivariable logistic regression and Spearman correlation analysis were performed to determine the risk factors for APOs in SLE. Results Risk factors for foetal loss included prepregnancy hypertension, hypocomplementaemia-C3, anticardiolipin antibodies-IgM positivity and disease flares during pregnancy. Risk factors for premature birth included disease flares, use of immunosuppressive agents and HDP. Moreover, twin pregnancy, disease flares and HDP were risk factors for SGA, and prepregnancy hypertension was an independent risk factor for asphyxia neonatorum. Independent risk factors for composite foetal APOs included twin pregnancy, prepregnancy hypertension, disease flares during pregnancy, HDP, hypocomplementaemia-C3 and the use of immunosuppressive agents. Risk factors for SLE complicated with HDP included prepregnancy hypertension, renal disorders and thrombocytopaenia. Conversely, the use of aspirin was a protective factor against foetal loss and premature birth. The ds-DNA value had a low diagnostic value for APOs, whereas the extent of complement reduction may predict the incidence of composite foetal APOs and foetal loss. Proteinuria occurring in the first 20 gestational weeks may lead to APOs. Conclusion Established risk factors for each APO were identified in this study. Indicators with more predictive significance have been screened out from conventional indicators, which may help clinicians predict the pregnancy outcome of patients with SLE more accurately and minimise the incidence of APOs.

medicine, general & internal
The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective

Arsenio Spinillo,Camilla Bellingeri,Irene De Maggio,Greta Riceputi,Maria Paola Pandolfi,Carolina Spada,Claudia Alpini,Carlomaurizio Montecucco,Fausta Beneventi

DOI: https://doi.org/10.1016/j.jri.2021.103304

Abstract:The aim of the study was to evaluate the rate of obstetric complications and the burden of obstetric outcomes in antiphospholipid syndrome (APS), non-criteria APS and asymptomatic antiphospholipid antibodies (aPL) carriers. From 2013-2018, 163 pregnant subjects with aPL antibodies and 785 controls were enrolled. Penalized logistic regression was used to compare obstetric complications. Cases included 62 complete APS (38 %), 48 non-criteria APS (29.4 %) and 53 (32.5 %) asymptomatic aPL-carriers. Connective tissue diseases (CTDs) were diagnosed in 31.3 % of cases. The rate of high-risk aPL profile was higher (p < .01) in APS (67.7 %) compared to non-criteria (14.6 %) and aPL-carriers (9.4 %). Double/triple positivity was 33.9 % (p < .05 compared to non-criteria and aPL-carriers) in APS, 10.4 % in non-criteria and 9.4 % in aPL-carriers. The rate of adverse pregnancy outcomes were 5.6 % in controls, 41.9 % (adj.OR = 6.95 %CI = 2.7-13.5) in APS, 25 % (adj.OR = 4.4,95 %CI = 2-9.4) in non-criteria and 28.3 % (OR = 4.95 %CI = 1.8-8.8) in aPL-carriers. CTDs were independently associated with an increased risk of adverse obstetric outcomes (OR = 2.8,95 %CI = 1.36-5.89). The attributable fraction (AF) of adverse obstetric events was higher among low-risk antibodies compared to high-risk (AF = 0.27,95 %CI = 0.22-0.31 vs AF = 0.16,95 %CI = 0.16-0.2,p < .01) and among single positivity compared to double/triple positivity (AF = 0.32,95 %CI = 0.26-0.37 vs AF = 0.11,95 %CI = 0.09-0.13,p < .01) suggesting that low-risk subjects are responsible for a high burden of obstetric complications.
Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

Yuke Hou,Lei Hou,Ziyi Song,Liang Luo,Jiayang Jin,Xuewu Zhang,Chun Li

DOI: https://doi.org/10.31083/j.ceog5104093

2024-01-01

Clinical and Experimental Obstetrics & Gynecology

Abstract:Background: Pregnancy complications of antiphospholipid syndrome (APS) are up to 20–30%. It is of great value to identify well-recognized predictors of adverse pregnancy outcomes (APOs) in APS. This study aims to explore the risk factors for APOs in patients with obstetric APS. Methods: This study included 142 women with APS delivered at Peking University People’s Hospital from February 2014 to August 2022. APOs included fetal death, neonatal death due to complications related to prematurity, preterm delivery <37 weeks due to placental insufficiency, hypertension, or preeclampsia, and small for gestational age (SGA) <10%. The association between pregnancy outcomes and clinical variables was assessed and the risk factors for APOs were analyzed. Results: APO occurred in 42.7% of pregnancies, including preterm delivery (23.4%), SGA (18.5%), and fetal death (6.5%). Patients in the APO group showed a significantly higher prevalence of underlying autoimmune disease (17% vs. 4.2%, p = 0.017) and lupus anticoagulant (LA) positivity (41.5% vs. 23.9%, p = 0.037) than those without APO. A significantly lower proportion of patients in the APO group were treated with low molecular weight heparin (LMWH) (58.5% vs. 76.1%, p = 0.037) and LMWH + low dose aspirin (LDA) (34.0% vs. 54.9%, p = 0.020) than in the non-APO group. Underlying autoimmune disease (odds ratio (OR): 5.147, 95% confidence interval (95% CI): 1.049–25.254, p = 0.043) was a risk factor for APOs and regular outpatient follow-up at the Department of Rheumatology and Immunology (OR: 0.429, 95% CI: 0.190–0.967, p = 0.041) was a protective factor for APOs. Conclusions: Underlying autoimmune disease is a risk factor for APOs and regular outpatient follow-up at the Department of Rheumatology and Immunology could be a protective factor for APOs.
An Approximation Algorithm for the Robot Localization Problem

Sven Koenig,Apurva Mudgal,C. Tovey

Abstract:Localization is a fundamental problem in robotics. The robot possesses line-of-sight sensors, a compass, and a map of its polygonal environment; it must determine its location at a minimum cost of travel distance. Localization is NP-hard [3], even to minimize within a c log n factor [15], where n is the number of polygon vertices. No approximation algorithm for the problem has been known. We give a strongly polynomial time O(log n log r)-factor approximation algorithm, where r is the number of reflex vertices. Technical features of the algorithm include a new edge-visibility based partition decomposition of the plane, and the idea of repeatedly planning travel on a “majority-rule” map, which permits a plan to be a route rather than a decision tree.
Impact of the 2023 ACR/EULAR Classification Criteria in Women with Primary Antiphospholipid Syndrome during Pregnancy

Víctor M. Martínez-Taboada,Ana Micieces Gómez,Sara del Barrio-Longarela,Ana Merino,Alejandra Comins-Boo,Marcos López-Hoyos,Leyre Riancho-Zarrabeitia,Rafael Gálvez,José L. Hernández

DOI: https://doi.org/10.3390/diagnostics14192162

IF: 3.6

2024-09-29

Diagnostics

Abstract:Background/Objectives: ACR/EULAR has recently developed new classification criteria for antiphospholipid syndrome (APS). The present study aims to analyze the impact of these new 2023 ACR/EULAR classification criteria in a cohort of pregnant women with primary APS. Methods: Retrospective cohort study of 93 consecutive pregnant women attending the Autoimmune Diseases Pregnancy Clinic, a multidisciplinary unit of a tertiary care teaching hospital, between 2005 and 2023. All of them fulfilled the Sydney classification criteria for APS. Women diagnosed with rheumatic autoimmune diseases other than APS were excluded. Results: Twenty-four out of ninety-three patients (25.8%) met the 2023 ACR/EULAR criteria for APS. Patients who met the new classification criteria were very similar to those who did not, except for being younger (p < 0.001), and had a lower number of clinical pregnancies (p = 0.004). The obstetric domain was clearly underrepresented in women who fulfilled the 2023 ACR/EULAR criteria (p < 0.001). Patients meeting the new classification criteria were primarily characterized by preterm births before 34 weeks due to severe placentation disorders (p = 0.004). Women with early and late fetal loss were significantly underrepresented (p < 0.0001 and 0.03, respectively). Nearly half of these patients had thrombocytopenia (p < 0.001). Serologically, these patients showed a higher frequency of persistent lupus anticoagulant (p = 0.02) and a lower frequency of IgM isotype antiphospholipid antibodies (p = 0.05). Conclusions: Almost three-quarters of the patients included in the study did not meet the 2023 ACR/EULAR criteria. Most patients who could not be classified according to these new classification criteria were those with early and/or late fetal deaths, as well as patients carrying only IgM aCL/AB2GPI antibodies. The high specificity of the 2023 ACR/EULAR criteria, restricted to severe placentation disorders, may leave the majority of patients with obstetric APS out of the new classification criteria.

medicine, general & internal
Risk factors associated with adverse pregnancy outcomes in patients with new-onset systemic lupus erythematosus during pregnancy

Jian Chen,Zi-Zi Xiao,Qing Shi,Hui-Min Wang,Fang He,Jian-Yu Zhang

DOI: https://doi.org/10.1177/0961203320980531

IF: 2.858

2021-01-06

Lupus

Abstract:Objective To investigate the risk factors for Adverse pregnancy outcome (APOs) in patients with new-onset SLE during pregnancy. Methods Eighty-five patients with new-onset SLE during pregnancy were analyzed retrospectively. Univariate and multivariate logistic regression were used to identify risk factors for different APOs (pregnancy loss, preterm birth, fetal growth restriction, and eclampsia/preeclampsia). A two-sided p-value below 0.05 was considered significant, and two-sided 95% confidence intervals (CIs) are reported. Results Multivariate analysis indicated that renal involvement (aOR: 7.356; 95%CI:1.516,35.692) and greater SLE disease activity index (SLEDAI) grade (aOR:5.947;95%CI: 1.586,22.294) increased the risk for composite APO, and that use of heparin therapy (aOR: 0.081; 95%CI: 0.012, 0.532) was a protective factor. Advanced gestational age at disease onset (aOR: 0.879; 95%CI: 0.819,0.943) and high serum albumin level (aOR: 0.908,95%CI: 0.831,0.992) protected against pregnancy loss. Renal involvement increased the risk for preterm birth (aOR: 2.272; 95%CI: 1.030,7.222) and fetal growth restriction (aOR: 9.070; 95%CI: 1.131,72.743). Hypertension (aOR: 19.185; 95%CI: 3.921,93.868), renal involvement (aOR: 8.380, 95%CI: 1.944,74.376) increased the risk for eclampsia/preeclampsia. Conclusion New onset SLE during pregnancy increased the risk for multiple APOs. Timely management of the risk factors identified here may help to improve pregnancy outcomes in these patients.

rheumatology
Clinical features and outcome of pregnancy with SLE-associated thrombocytopenia.

Xue Xu,Mei-Ying Liang,Jian-Liu Wang,Shi Chen

DOI: https://doi.org/10.3109/14767058.2015.1018169

2016-01-01

Abstract:Objective: To analyze the course of maternal diseases and compare pregnancy outcomes in patients with systemic lupus erythematosus (SLE)-associated thrombocytopenia to patients without.Methods: Medical charts of 77 pregnancies in 73 SLE patients were systematically reviewed. Patients were divided into two groups according to the presence or absence of thrombocytopenia. Patients who are new onset SLE during pregnancy were also been studied.Result: Thrombocytopenia was found in 18 (23.3%) of the pregnancies. SLE patients with thrombocytopenia during pregnancy had higher percentage of disease flaring (11/18 versus 14/59, p=0.003) and SLE-Pregnancy Disease Activity Index (7.896.192 versus 2.41 +/- 3.3.89, p=0.001) compared to patients without. Also, patients with thrombocytopenia had a higher percentage of pulmonary, cardiac and multiple organ system involvement. There was a statistically significant difference in preeclampsia and early onset hypertensive disorder induced before 34 weeks as well as the rate of live birth less than 34 weeks (33.3% versus 6.8%, p=0.003 & 38.9% versus 13.6%, p=0.018 & 16.7% versus 1.7%, p=0.038). Patients with thrombocytopenia suffered from higher rate of pregnancy loss (22.2% versus 3.4%, p=0.024) and neonatal death (33.3% versus 1.7%, p=0.000). In our study there were 17 patients with new-onset of SLE during pregnancy. The hematological system manifestation occurred in all of them and there was a significant increase in the incidence of thrombocytopenia (n=12, 70.6%).Conclusion: Thrombocytopenia in SLE during pregnancy indicates higher disease activity, severe organ damage, early onset preeclampsia and higher pregnancy loss.
Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus

Zhongping Zhan,Ying Yang,Yanfeng Zhan,Dongying Chen,Liuqin Liang,Xiuyan Yang

DOI: https://doi.org/10.1371/journal.pone.0176457

IF: 3.7

2017-04-25

PLoS ONE

Abstract:This study aims to investigate the fetal outcomes and associated factors of adverse pregnancy outcomes (APOs) in pregnant women with systemic lupus erythematosus (SLE). Clinical data from 251 SLE patients with 263 pregnancies from 2001 to 2015 were analyzed retrospectively. APOs occurred in 70.0% of pregnancies, in which pregnancy loss occurred in 28.5%; preterm delivery occurred in 21.3%; intrauterine growth retardation occurred in 12.2%; and fetal distress occurred in 8.0%. Over time, the rate of APOs decreased from 82.8% during 2001~2005 to 59.6% during 2011~2015. In multivariate analysis, predictors of APOs included positive antiphospholipid antibodies (OR 8.4, 95% CI 1.7~40.8, P = 0.008), lower complement (OR 3.6, 95% CI 1.3~9.9, P = 0.01), hypoalbuminemia (OR 3.2, 95% CI 1.2~8.3, P = 0.02), and hypertension (OR 14.6, 95% CI 1.5~141.6, P = 0.02). The use of antimalarial medications was associated with lower risk for APOs (OR 0.3, 95% CI 0.1~0.7, P = 0.01). In total, 109 patients underwent fetal umbilical artery Doppler in the third trimester. The The adjusted systole/diastole (S/D) ratio, pulsatility index (PI) and resistance index (RI) of SLE patients with APOs were higher than that of patients without APOs (2.9±0.9 vs. 2.4±0.5, P = 0.001). Lupus pregnancy was still at high risk of APOs in terms of pregnancy loss and preterm delivery. Umbilical artery Doppler was a good monitor method for APOs in the third trimester.

multidisciplinary sciences

[The ophthalmic zona-ipsilateral cerebral ischemia syndrome].

[Analysis of pregnancy outcomes, disease progression, and risk factors in patients with undifferentiated connective tissue disease].

Research Progress on the Relationship between Anticardiolipin Antibodies and Adverse Pregnancy Outcomes

Discharge pattern of tonically activated motor units during unloading.

Placental histology and neutrophil extracellular traps in lupus and pre-eclampsia pregnancies

OA22 Pregnancy in connective tissue diseases: a 30 year follow-up study of 465 pregnancies from a Spanish monocentric registry

Undifferentiated connective tissue diseases and adverse pregnancy outcomes. An undervalued association?

Biochemical and clinical predictors in pregnant women with antiphospholipid syndrome and systemic lupus erythematosus: comprehensive update

Related Factors of Fetal Loss in Chinese Women with Systemic Lupus Erythematosus: Data from Chinese SLE Treatment and Research Group Registry IV

Placental damage in pregnancies with systemic lupus erythematosus: A narrative review

Pregnancy outcomes and risk factors analysis in patients with systemic lupus erythematous

Effects of Perinatal Disease Activity on Offspring's Growth in Patients with Systemic Lupus Erythematosus

A Comparison of Obstetric Outcomes in Antiphospholipid Syndrome Among Pregnant Women With Systemic Lupus Erythematosus

High-risk factors for adverse pregnancy outcomes in systemic lupus erythaematosus: a retrospective study of a Chinese population

The impact of various entities of antiphospholipid antibodies positivity on adverse pregnancy outcome. An epidemiological perspective

Risk Factors for Adverse Pregnancy Outcomes in Patients with Antiphospholipid Syndrome

An Approximation Algorithm for the Robot Localization Problem

Impact of the 2023 ACR/EULAR Classification Criteria in Women with Primary Antiphospholipid Syndrome during Pregnancy

Risk factors associated with adverse pregnancy outcomes in patients with new-onset systemic lupus erythematosus during pregnancy

Clinical features and outcome of pregnancy with SLE-associated thrombocytopenia.

Fetal outcomes and associated factors of adverse outcomes of pregnancy in southern Chinese women with systemic lupus erythematosus